Skip to main navigation Skip to search Skip to main content

A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

  • Johann Tang
  • , Scott Williams
  • , Keen-Hun Tai
  • , Joanne Dean
  • , Gillian Duchesne

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We analyzed data from 88 patients with T1aa??T3a, N0, M0 prostate adenocarcinoma treated on a prospective Phase I/II HDRB boost protocol of 16 or 20 Gy in four fractions, without planned androgen deprivation therapy.
Original languageEnglish
Pages (from-to)256 - 261
Number of pages6
JournalBrachytherapy
Volume5
DOIs
Publication statusPublished - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this